- First patient in the world treated with Alpha DaRT ®  in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months – - This pilot study is a key part of Alpha Tau’s broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs - Jerusalem, December 9, 2025 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW)

Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026 JERUSALEM, December 4, 2025 -- Alpha Tau Medical Ltd.  ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today that two abstracts have been accepted to the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, to be held

- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer -   JERUSALEM, December 2, 2025 – Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with locally recurrent prosta

JERUSALEM, December 1, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will presentation in the following investor conferences in December 2025.   Event: 37th Annual Piper Sandler Healthcare Conference Format: Fireside Chat Date: December 3, 2025 Time: 1:00 – 1:25PM ET Location: New York, NY   Event: Sidoti's Year End Virtual

Dr. Blumenfeld*, what drew you to participate in the Alpha DaRT clinical trial for lung cancer? Alpha DaRT is a very exciting modality with significant potential for the future of radiation oncology. As radiation oncologists, we are always striving to improve what we call the therapeutic ratio: delivering a dose high enough to destroy the tumor while also minimizing harm to healthy tissues. From my experience, Alpha DaRT is unique in its ability to deliver ultra-high, highly

- Alpha DaRT pancreatic cancer patient treatments underway in U.S. multi-center pilot study - - Newly received radioactive material license for New Hampshire facility positions the Company for continued advancement towards commercial readiness - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART trial - - Cash, cash equivalents & deposits balance of $75.9 million provides runway for continued

Receiving a diagnosis of pancreatic cancer can be devastating, and all too often it arrives at a stage where surgical removal is no longer an option. This is because pancreatic cancer is frequently silent until it progresses; by the time symptoms appear, the disease has often spread beyond the pancreas. Yet, despite its grim reputation, there are promising advances in both detection and treatment - from refined chemotherapy to radiation innovations and participation in clinic

JERUSALEM, November 11, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will participate at the Jefferies Global Healthcare Conference in London on November 18-19, 2025. Event: Jefferies Global Healthcare Conference Format: 1X1 Investor meetings Date: November 18-19, 2025 Location: London   Mr. Levy will be available for 1x1 i

Dr. Harold Jacob Director of Advanced Gastrointestinal Endoscopy Hadassah University Medical Center Alpha TAU Medical VP Marketing Gideon Matthews, PhD recently sat with Dr. Harold Jacob, Director of Gastrointestinal Endoscopy, Hadassah University Medical Center, to discuss currently ongoing clinical trials of the Alpha DaRT® for the treatment of pancreatic cancer at Hadassah.   You have many decades of experience as a physician and gastroenterologist. What drew you to join t

- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation - - License paves way for introduction of radioactive material and continued positive momentum toward initiating Alpha DaRT treatment manufacturing in 2026 - Jerusalem, October 21, 2025 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the deve